Former Acting Chief Financial Officer · Janux Therapeutics, Inc. (JANX)

Tighe Reardon

FY2024 is the first fiscal year CompBrief holds for Tighe Reardon as a named executive officer of Janux Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$7,913,496

Salary $0Stock awards $0

2nd of 4 named executive officers at Janux Therapeutics by FY2024 total.

4 named officers on file for Janux Therapeutics, FY2024

Tighe Reardon’s pay file — $29

  • 1 fiscal year of pay, line by line
  • JANX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Janux Therapeutics’s whole pay program stands against its peers

  • Janux Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on JANX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2025 (DEF 14A).

Free

Get Tighe Reardon’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Tighe Reardon compensation by year

Janux Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Janux Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$0
Bonus$0
Stock awards$0
Option awards$7,913,496
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$7,913,496

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Janux Therapeutics, Inc. DEF 14A filed April 25, 2025, accession 0000950170-25-058806, and prior-year filings.

How this page was built: the Janux Therapeutics, Inc. filed document, accession 0000950170-25-058806. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option20,016—$10.59
Option31,620—$20.24
Option41,250—$14.02
Option94,854—$11.02

Per the Outstanding Equity Awards at Fiscal Year-End table in Janux Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Janux Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
David CampbellPresident and Chief Executive Officer$8,974,873
Tighe Reardon · this pageFormer Acting Chief Financial Officer$7,913,496
Byron RobinsonChief Strategy Officer$3,815,641
Thomas DiRaimondoChief Scientific Officer$3,414,644

The full Janux Therapeutics compensation record

free company brief

This page is one person within Janux Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Janux Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Janux Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Tighe Reardon's compensation dossier · One-time report. No refunds.